In vivo Hybridoma Approach to Identify Novel Therapeutic- and Diagnostic-Grade Antibodies
The LakePharma hybridoma platform offers a variety of high-performance hybridoma technologies to discover great antibodies. The specific discovery approach depends on project-intrinsic parameters. These comprise practical (client resource, timeline) and scientific considerations. For the latter, we perform a rigorous upfront target analysis to devise the best discovery approach. Here we use bioinformatics, literature, and patent data to identify target-specific considerations that could impact our discovery efforts. This due diligence helps ensure that we are following an optimal path for antibody discovery from the outset.